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this study analyzed clinical outcomes of ﬂowable hemostatic
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Design: Retrospective database analysis of cardiac surgi-
cal cases from 2006 to 2012.
Setting: Data were extracted from Premier’s United
States (US) Perspective Database, developed for quality
and utilization benchmarking and containing approximately
25% of US hospital discharges.
Participants: Coronary artery bypass grafting (CABG),
aortic, valve, or valvular with CABG surgery cases in which
FLOSEAL or SURGIFLO was included.
Interventions: Three study groups were formed, given
usage of hemostatic matrices: (1) FLOSEAL or SURGIFLO,
exclusively; (2) FLOSEAL or SURGIFLO, with ﬁbrin sealants,
sealants, or powder hemostats; and (3) FLOSEAL or SURGI-
FLO, with nonﬂowable hemostats with or without thrombin.
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1558 Journal of Cardiothoracic anMeasurements and Main Results: Group A included 4,480
FLOSEAL and 326 SURGIFLO cases. Results suggested SUR-
GIFLO cases were associated with signiﬁcantly higher risk of
multiple adverse outcomes, including major (odds Ratio [OR]
2.12; 95% CI 1.34-3.35; p ¼ 0.001) and minor complications
(OR 1.84; 95% CI 1.33-2.55; po 0.001); surgical revisions (OR
2.01; 95% CI 1.03- 3.94; p ¼ 0.042); transfusions for any blood
products (OR 4.90; 95% CI 3.50-6.87; po 0.001); and longer
surgery times (adjusted mean difference ¼ 64 minutes,
po 0.001) than the FLOSEAL group. There were no signiﬁ-
cant differences in mortality and LOS. Results were similar
in groups B and C.
Conclusions: These retrospective outcomes suggested
FLOSEAL was associated with fewer negative conse-
quences than SURGIFLO in this surgical population.
& 2014 The Authors. Published by Elsevier Inc. All rights
reserved.
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hemostasisACHIEVING HEMOSTASIS intraoperatively and postop-eratively is a critical requirement of surgery. Failure to
maintain hemostasis can result in excessive bleeding, thereby
complicating surgery and increasing the risk of morbidity and
mortality.1–3 In a retrospective analysis of more than 1.6
million surgeries performed in the United States (US), Stokes
et al reported 45.8% of cardiac patients required blood trans-
fusions, and across multiple surgery types, nearly 30% of
patients experienced bleeding-related complications.4
Topical hemostats often are used by surgeons to treat bleeding
during surgery when bleeding cannot be controlled by conven-
tional methods (eg, suturing, cautery, or manual compression) or
when conventional methods are impractical.5–8 Topical hemostats
can be categorized as passive or active, referring to the
mechanism of action the agent provides during surgery. Passive
agents act via bleeding site contact activation and promotion of
platelet aggregation, and include collagens, cellulose, gelatins,
and polysaccharide spheres. Active agents act biologically on the
clotting cascade and include thrombin. Categories comprised of
active agents are ﬂowable topical hemostats and sealants,
including ﬁbrin sealants, polyethylene glycol (PEG) polymers,
albumin and glutaraldehyde, and cyanoacrylate.9,10The most commonly used topical hemostats, alone or
in combination, include gelatin and thrombin.5 Commonly
used gelatin-thrombin-based ﬂowable topical hemostats are
FLOSEAL Hemostatic Matrix (Baxter Healthcare Corporation,
Deerﬁeld, IL) and SURGIFLO Hemostatic Matrix (Ethicon
Incorporated, Somerville, NJ) and are advantageous in surgery
because they can conform to wound contours and ﬁll deep
lesions. Both products have been labeled as hemostatic matrices
and have dual mechanisms of action in the blood clotting cascade
via contact activation and active biologic agents (eg, thrombin).
Since the early 2000s, a steady number of prospective,
randomized, controlled trials have reported greater clinical value
in ﬂowable (FLOSEAL Hemostatic Matrix) versus nonﬂowables
(GELFOAM with or without thrombin or SURGICEL) hemo-
static agents.6,11–13 Nasso et al compared outcomes associated
with FLOSEAL (an active agent) to either oxidized regenerated
cellulose SURGICEL Nu-Kit or puriﬁed porcine gelatin sponge
GELFOAM 12 (both passive agents) in 415 patients undergoing
elective cardiac and/or thoracic aortic surgeries.6 Results showed
patients treated with the ﬂowable hemostatic matrix (FLOSEAL)
for intraoperative bleeding experienced shorter hemostasis time
(minutes) (po 0.001), lower rates of blood products (po 0.001)
and blood transfusions (po 0.001), but also experienced lower
rates of revisions for bleeding (po 0.04) and minor complica-
tions (po 0.04), compared with other agents. Furthermore, the
overall study found lower postoperative bleeding and a lower rate
of blood transfusion in the FLOSEAL group (po 0.001).
Two animal studies directly compared active ﬂowable hemo-
static matrices. Lewis et al conducted a study comparing FLO-
SEAL and SURGIFLO þ thrombin in a heparinized porcine liver
model.5 Coenye et al compared the effectiveness of the same active
ﬂowable hemostats in traumatized porcine liver models.14 These
animal studies reported faster and more effective hemostasis with
FLOSEAL compared with SURGIFLO þ thrombin. Simulated
methods from these studies also indicated that the two active
ﬂowable hemostats had differently shaped gelatin granules (Fig 1).d Vascular Anesthesia, Vol 28, No 6 (December), 2014: pp 1558–1565
Fig 1. Scanning electron microscopic images of (A) bovine-
derived gelatin (FLOSEAL) and (B) porcine-derived gelatin (SURGI-
FLO). Samples of each hemostat were dehydrated in a graded
ethanol series to 100% ethanol. They then were placed into graded
solutions of ethanol and hexamethyldisilazane (HMDS), followed by
fresh 100% HMDS, and allowed to air dry. The specimens then were
mounted onto aluminum SEM supports with carbon tape and coated
with palladium for conductivity using a Denton Desk IV Sputter/Etch
Unit (Denton Vacuum, LLC, Moorestown, NJ). Samples then were
examined morphologically using a Jeol JSM-7600F Scanning Elec-
tron Microscope (Jeol USA, Inc, Peabody, MA) and representative
images were taken. [Baxter data on ﬁle]
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the effectiveness and clinical outcomes of active ﬂowable
versus passive nonﬂowable hemostatic agents. The two animal
studies by Lewis et al and Coenye et al suggested that active
ﬂowable hemostatic agents may perform differently. However,
no studies have compared outcomes (such as signiﬁcant
complications and healthcare resource use) associated with
active ﬂowable agents in a human population. Given the low
incidence of various signiﬁcant complications from surgery, the
authors of the present study determined that the best approach
would be to use a large patient registry database for quality and
utilization measurement to derive outcomes. As such, the
objective of this study was to evaluate “real-world” outcomes
of active ﬂowable hemostatic matrices (FLOSEAL andSURGIFLO kits) among a large cardiac surgery population,
using clinical parameters similar to those assessed by Nasso
et al, from a large US hospital database.
PATIENTS AND METHODS
A retrospective analysis assessing clinical outcomes associated with
active ﬂowable hemostatic matrices was conducted using Premier’s US
Perspective Hospital Database.
Data were extracted from Premier’s US Perspective Hospital Data-
base, which was developed for quality and utilization benchmarking and
contains more than 490 million hospital encounters, with approximately
6 million added each month. Currently, it is estimated that this database
captures approximately 1 of every 4 hospital discharges in the US.15
Data contain a date-stamped log of all billed items, including procedures,
diagnoses, medications, laboratory, diagnostic/therapeutic services, costs,
drugs, and medical devices received at the individual patient level during
the hospitalization. Data are de-identiﬁed in accordance with compliance
of the US Health Insurance Portability and Accountability Act (HIPAA)
to protect patient conﬁdentiality. As such, there was no requirement for
internal review board approval or exemption, because the study met all
current criteria set forth by the United States Department of Health and
Human Services (HHS).
After extraction of cardiac surgical cases, real-world usage of the two
kitted products was evaluated. The study objective was to evaluate
outcomes associated with FLOSEAL and SURGIFLO only in the real-
world surgical population. This objective was met via the formation of
Group A (FLOSEAL or SURGIFLO only; ie, sole use of the product
only). However, upon investigation, two other very distinct usage patterns
of these products used concomitantly with other types of active and
passive hemostats and sealants were found in this surgical population. As
a result, outcomes in these two additional groups (B and C) were
assessed: group B (FLOSEAL or SURGIFLO only, combined () with
other commonly accepted ﬁbrin sealants, sealants, or powder hemostat
products) and group C (FLOSEAL or SURGIFLO only, combined ()
with other commonly accepted nonﬂowable hemostats with and without
thrombin) To clarify, group B represented use of kitted FLOSEAL or
SURGIFLO only, combined with EVITHROM, TISSEEL, EVICEL,
COSEAL, BIOGLUE, and ARISTA, and group C represented use of
kitted FLOSEAL or SURGIFLO only, combined with EVITHROM,
GELFOAM, GELFOAM Plus (thrombin), SURGICEL, and stand-alone
thrombin. These 3 groups (A, B, and C) served as a basis for the analyses
to evaluate real-world usage and clinical outcomes (Fig 2).
Patients included in the analysis were hospitalized for elective,
emergent, or urgent cardiac surgeries, with hospitalizations and discharges
occurring between January 1, 2006 and September 30, 2012. Patients
underwent either coronary artery bypass grafting (CABG), aortic, valve, or
valvular with CABG procedures, as classiﬁed by primary or secondary
ICD-9 procedure codes and analogous to the Nasso et al study. Further
selection criteria required that all patients be administered heparin and
protamine as a standard of care and that patients intraoperatively received
one of the most commonly used active ﬂowable gelatin hemostatic matrices
(either FLOSEAL or SURGIFLO, but not both). Patients with missing
baseline values (eg, gender or admission source) or cardiac surgeries
shorter than 90 minutes or longer than 720 minutes, representing outliers of
approximately the lower and upper 1%, were excluded from all groups.
Patient characteristics included in the analysis were age, sex (male/
female), race (white/black/other), Charlson comorbidity index (CCI)
score,16 procedure type (aortic, CABG, valve, or other [aortic, CABG,
or valve as a secondary procedure]), and admission type (elective,
emergent, or urgent). Hospital variables included teaching or non-
teaching hospital, US region, and bed size.
Studied outcomes analogous to the Nasso et al study6 included
major postoperative complication (stroke, shock, sepsis or septicemia,
and myocardial infarction), minor postoperative complication (renal
Fig 2. Patient selection. *Represents 1 out of every 4 hospital discharges in United States.
TACKETT ET AL1560failure, respiratory insufﬁciency, and inotropic support lasting more
than 24 hours), surgical revision for bleeding (return to the operating
room to address surgical bleeding by identiﬁcation of the ICD-9 code
for a rethoracotomy to an existing surgical site within the same
hospitalization) and inpatient mortality. Other healthcare utilization
outcomes included blood-product administration: Any blood-product
transfusions overall; any day 1 (surgery start to end of the ﬁrst day) and
postoperative days 2-4 blood-product transfusions; any packed red
blood cell [PRBC] transfusions; and transfused units of blood products
and PRBCs. Additional healthcare resource utilization outcomes were
hospital length of stay (LOS) in days and surgery time in minutes.
Descriptive analyses were conducted on all key variables. The chi-
square and Student’s t tests were used to evaluate study groups. Logistic
regression models were used to estimate risk of complications, surgical
revision, inpatient mortality, and transfusions.17 Generalized linear models
(GLM) with log link and negative binomial distribution (negative
binomial regression) were used to compare surgery time, LOS, and
transfused units of blood products. Approximately the lower and upper
1% of the distribution for LOS were excluded from GLMs. Patients
missing baseline values (eg, gender or severity of illness codes) or cardiac
surgeries shorter than 90 minutes or longer than 720 minutes (representing
outliers of approximately the lower and upper 1%) were excluded. Patients
missing transfusions unit values (ie, 0 units) or values greater than 50 units
were excluded from transfusion unit GLMs to eliminate outliers.
Values for unadjusted outcome rates (eg, major complications) and
adjusted odds ratios were reported from logistic regression analyses, and
adjusted differences from expected number of outcomes (eg, LOS) were
reported from GLM analyses. Study covariates used were age, sex, race, CCI
score, procedure type, admission type, hospital teaching status, hospital bed
size, and US region. SAS version 9.3 (SAS Institute Inc, Cary, NC)18 was
used to perform statistical analyses with a priori signiﬁcance level of 0.05.RESULTS
A total of 314,415 cardiac surgery cases were identiﬁed. A
total of 4,806, 8,376, and 10,916 cases met inclusion criteria
for groups A, B, and C, respectively. Select surgical patient and
provider characteristics can be found in Table 1.Outcomes from logistic and GLM regression analyses are
presented in Tables 2, 3, and 4 for groups A, B, and C,
respectively. All modelsʼ measures of goodness of ﬁt were
found to be acceptable. All logistic models had c-statistic
values ranging from 0.7 to 0.8. All GLMs had scaled deviance
values/DF ranging from 0.9 to 1.0.Group A: FLOSEAL versus SURGIFLO, Only
Complications
SURGIFLO-treated cases were associated with a higher risk
of experiencing major complications (OR = 2.12; 95% CI =
1.34-3.35; p = 0.001), minor complications (OR = 1.84; 95%
CI = 1.33-2.55; po 0.001), and surgical revision for bleeding
(OR = 2.01; 95% CI = 1.03-3.94; p = 0.042) compared with
FLOSEAL-treated cases. No signiﬁcant differences were found
in mortality (OR = 0.79; 95% CI = 0.38-1.65; p = 0.53).Blood Product Administration
Patients treated by SURGIFLO were associated with
an increased risk for transfusions: Any blood product overall
(OR = 4.90; 95% CI = 3.50-6.87; p o 0.001), day 1
transfusion (OR = 10.53; 95% CI = 7.68-14.43;
p o 0.001), and PRBC (OR = 2.64; 95% CI = 1.97-3.55;
p o 0.001) compared with FLOSEAL. No signiﬁcant differ-
ences were found in day 2 to day 4 transfusions (OR = 0.94;
95% CI = 0.71-1.25; p = 0.69).
SURGIFLO patients received more transfused units: Overall
blood product (adjusted difference [AD] = 5.66 units;
po 0.001), day 1 blood products (AD = 3.16 units;
po 0.001), and PRBC (AD = 2.45 units; po 0.001) com-
pared with FLOSEAL patients. However, SURGIFLO cases
received fewer day 2 to day 4 blood products (AD = –0.7 units;
p = 0.012) than FLOSEAL patients.
Table 1. Select Surgical Patient and Provider Characteristics*
Patient Characteristics
Group A Group B Group C
FLOSEAL
n (%)
SURGIFLO
n (%) p value
FLOSEAL
n (%)
SURGIFLO
n (%) p value
FLOSEAL
n (%)
SURGIFLO
n (%) p value
Total number of cases 4,480 326 N/A 7,730 646 N/A 10,180 736 N/A
Age: mean (SD) 64.6 (12.7) 67.8 (11.4) o0.001 65.2 (12.8) 66.9 (12.0) o0.001 65.2 (12.9) 66.6 (12.2) 0.003
Gender
Female 1,336 (29.8) 116 (35.6) 0.03 2,406 (31.1) 212 (32.8) 0.37 3,109 (30.5) 234 (31.8) 0.48
Male 3,144 (70.2) 210 (64.4) 5,324 (68.9) 434 (67.2) 7,071 (69.5) 502 (68.2)
Race
White 3,628 (81.0) 257 (78.8) o0.001 6,220 (80.5) 472 (73.1) o0.001 8,356 (82.1) 538 (73.1) o0.001
Black 270 (6.0) 4 (1.2) 380 (4.9) 12 (1.9) 634 (6.2) 27 (3.7)
Other 582 (13.0) 65 (19.9) 1,130 (14.6) 162 (25.1) 1,190 (11.7) 171 (23.2)
CCI score
0 734 (16.4) 63 (19.3) 0.53 1,233 (16.0) 119 (18.4) 0.02 1,620 (15.9) 113 (15.3) 0.004
1 1,149 (25.6) 85 (26.1) 2,012 (26.0) 162 (25.1) 2,649 (26.0) 175 (23.8)
2 1,098 (24.5) 66 (20.3) 1,811 (23.4) 120 (18.6) 2,353 (23.1) 141 (19.2)
3 664 (14.8) 46 (14.1) 1,192 (15.4) 97 (15.0) 1,505 (14.8) 115 (15.6)
4 383 (8.6) 28 (8.6) 711 (9.2) 62 (9.6) 936 (9.2) 81 (11.0)
5 236 (5.3) 18 (5.5) 374 (4.8) 45 (7.0) 548 (5.4) 53 (7.2)
Z6 216 (4.8) 20 (6.1) 397 (5.1) 41 (6.4) 569 (5.6) 58 (7.9)
Primary procedure
Aortic surgery 21 (0.5) 2 (0.6) o0.001 91 (1.2) 10 (1.6) o0.001 113 (1.1) 5 (0.7) o0.001
CABG surgery 3,194 (71.3) 156 (47.9) 4,717 (61.0) 334 (51.7) 6,394 (62.8) 397 (53.9)
Valve surgery 1,042 (23.3) 162 (49.7) 2,477 (32.0) 286 (44.3) 3,063 (30.1) 309 (42.0)
Other 223 (5.0) 6 (1.8) 445 (5.8) 16 (2.5) 610 (6.0) 25 (3.4)
Admission type
Elective 2,389 (53.3) 182 (55.8) 0.29 4,425 (57.2) 323 (50.0) o0.001 5,629 (55.3) 385 (52.3) 0.11
Emergent 1,137 (25.4) 70 (21.5) 1,744(22.6) 154 (23.8) 2,359 (23.2) 169 (23.0)
Urgent 954 (21.3) 74 (22.7) 1,561 (20.2) 169 (26.2) 2,192 (21.5) 182 (24.7)
Provider characteristics
Number: Hospital/physician 95/639 11/69 N/A 118/1,011 18/99 N/A 133/1,390 21/132 N/A
Teaching hospital
Yes 1,318 (29.4) 22 (6.7) o0.001 3,245 (42.0) 95 (14.7) o0.001 4,704 (46.2) 169 (23.0) o0.001
No 3,162 (70.6) 304 (93.3) 4,485 (58.0) 551 (85.3) 5,476 (53.8) 567 (77.0)
US region
East 442 (9.9) 7 (2.2) o0.001 1,364 (17.7) 15 (2.3) o0.001 1,997 (19.6) 23 (3.1) o0.001
Central 1,693 (37.8) 267 (81.9) 3,001 (38.8) 414 (64.1) 4,181 (41.1) 452 (61.4)
West 2,345 (52.3) 52 (15.9) 3,365 (43.5) 217 (33.6) 4,002 (39.3) 261 (35.5)
Bed size
0-199 49 (1.1) 28 (8.6) o0.001 165 (2.1) 148 (22.9) o0.001 244 (2.4) 142 (19.3) o0.001
200-299 356 (7.9) 8 (2.5) 515 (6.7) 56 (8.7) 859 (8.4) 102 (13.9)
300-499 2,806 (62.6) 253 (77.6) 4,647 (60.1) 332 (51.4) 5,055 (49.7) 292 (39.7)
500þ 1,269 (28.3) 37 (11.3) 2,403 (31.1) 110 (17.0) 4,022 (39.5) 200 (27.2)
Abbreviations: CABG, coronary artery bypass grafting; CCI, Charlson Comorbidity Index; N/A, not applicable; SD, standard deviation.
*All data are n (%) unless otherwise stated. All p values are from chi-square test for categoric variables and Student’s t test for continuous
variables.
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No signiﬁcant differences were found for hospital LOS (AD =
–0.24 days; p = 0.51). SURGIFLO patients had longer surgery
times (AD = 64 minutes; po 0.001) than FLOSEAL patients.
Group B: FLOSEAL or SURGIFLO, Only, Combined ()
with Other Commonly Accepted Fibrin Sealants,
Sealants or Powder Hemostat Products
Complications
SURGIFLO-treated patients were associated with a higher risk
for major (OR = 1.77; 95% CI = 1.28-2.46; po 0.001) andminor complications (OR = 1.46; 95% CI = 1.16-1.83; p = 0.001)
than FLOSEAL-treated patients. No signiﬁcant differences were
found for surgical revisions (OR = 1.26; 95% CI = .76-2.09; p =
0.36) and mortality (OR = 1.09; 95% CI = .68-1.74; p = 0.71).
Blood Product Administration
SURGIFLO patients were associated with an increased risk
for transfusions: Any blood-product (OR = 8.37; 95% CI =
6.60-10.62; po 0.001), day 1 (OR = 10.36; 95% CI = 8.32-
12.90; po 0.001) and day 2 to day 4 blood products (OR =
1.97; 95% CI = 1.62-2.40; po 0.001), and overall PRBC
(OR = 5.63; 95% CI = 4.55-6.97; po 0.001).
Table 2. Results of Group A: FLOSEAL Only (reference group) compared with SURGIFLO Only
Comparative Outcomes
FLOSEAL
(N ¼ 4,480)
SURGIFLO
(N ¼ 326)
Odds Ratio (95% CI)*/
Adjusted Difference†
Relative Risk‡
(95% CI) p value§
Major complications: n (%)¶ 389 (8.7) 32 (9.8) 2.12 (1.34-3.35) 2.01 (1.32-3.03) 0.001
Minor complications: n (%)¶ 779 (17.4) 76 (23.3) 1.84 (1.33-2.55) 1.54 (1.23-1.88) o0.001
Surgical revision: n (%)¶ 86 (1.9) 14 (4.3) 2.01 (1.03- 3.94) 1.94 (1.02-3.54) 0.042
Patient mortality: n (%)¶ 108 (2.4) 11 (3.4) 0.79 (0.38-1.65) 0.80 (0.39-1.61) 0.53
Any blood product transfusion: n (%)¶ 1,811 (40.4) 272 (83.4) 4.90 (3.50-6.87) 1.62 (1.52-1.69) o0.001
AM units (95% CI)† 8.54 (7.44-9.82) 14.21 (11.92-16.93) 5.66 units N/A o0.001
Day 1, blood product transfusion: n (%)¶ 1,148 (25.6) 263 (80.7) 10.53 (7.68-14.43) 2.74 (2.56-2.88) o0.001
AM units (95% CI)† 6.85 (5.81-8.08) 10.01 (8.20-12.22) 3.16 units N/A o0.001
Day 2-4, blood product transfusion: n (%)¶ 887 (19.8) 113 (34.7) 0.94 (0.71-1.25) 0.96 (0.78-1.16) 0.69
AM units (95% CI)† 3.36 (2.82-4.02) 2.67 (2.10-3.38) –0.7 units N/A 0.012
PRBC transfusion: n (%)¶ 1,654 (36.9) 238 (73.0) 2.64 (1.97-3.55) 1.48 (1.34-1.60) o0.001
AM units (95% CI)† 6.60 (5.77-7.53) 9.04 (7.66-10.67) 2.45 units N/A o0.001
Hospital LOS: AM (95% CI)† 12.39 (11.68-13.15) 12.15 (11.23-13.15) –0.24 days N/A 0.51
Surgery time: AM (95% CI)† 375 (362-388) 439 (419-459) 64 minutes N/A o0.001
Abbreviations: AM, adjusted mean; CI, conﬁdence interval; LOS, length of stay; N/A, not applicable; PRBC, packed red blood cell.
*Odds ratios from logistic regression for all binary outcome variables.
†Ratios and adjusted mean value for each group from GLM-negative binomial regression analyses.
‡Relative risk converted from adjusted odds ratio and percentage of event in each group
§All p values from logistic regressions or GLM.
¶n (%) from unadjusted frequency tables.
TACKETT ET AL1562SURGIFLO-treated patients received more transfused units
of any blood product (AD = 4.15 units; po 0.001), day 1
(AD = 1.76 units; po 0.001), and PRBC (AD = 1.86 units;
p o 0.001) compared with FLOSEAL-treated patients. No
signiﬁcant differences were found for day 2 to day 4 blood
product transfusion units (AD = –0.12 units; p = 0.66).
Healthcare Utilization
SURGIFLO-treated patients had longer surgery times (AD =
22 minutes; po 0.001), compared with FLOSEAL patients. No
difference were found for hospital LOS (AD = 0.17 days;
p = 0.53).TABLE 3. Results of Group B. FLOSEAL Only () Any Fibrin Sealant,
Comparative Outcomes
FLOSEAL
(N ¼ 7,730)
Major complications: n (%)¶ 579 (7.5) 6
Minor complications: n (%)¶ 1,382 (17.9) 15
Surgical revision: n (%)¶ 203 (2.6) 2
Patient mortality: n (%)¶ 226 (2.9) 2
Any blood product transfusion: n (%)¶ 2,899 (37.5) 52
AM Units (95% CI)† 9.81 (8.93-10.79) 13.9
Day 1, blood product transfusion: n (%)¶ 2,019 (26.1) 49
AM units (95% CI)† 8.00 (7.12-8.99) 9.7
Day 2-4 blood product transfusion: n (%)¶ 1,297 (16.8) 23
AM units(95% CI)† 3.98 (3.49-4.54) 3.8
PRBCs transfusion: n (%)¶ 2,499 (32.3) 47
AM units (95% CI)† 7.76 (7.04-8.55) 9.6
Hospital LOS: AM (95% CI)† 12.56 (12.12-13.02) 12.7
Surgery time: AM (95% CI)† 387 (379-396) 40
Abbreviations: AM, adjusted mean; CI, conﬁdence interval; LOS, length
*Odds ratios from logistic regression for all binary outcome variables.
†Ratios and adjusted mean value for each group from GLM negative b
‡Relative risk converted from adjusted odds ratio and percentage of ev
§P-value from logistic regressions or GLM.
¶n (%) from unadjusted frequency tables.Group C: FLOSEAL or SURGIFLO, Only Combined ()
with Commonly Accepted Nonﬂowable Hemostats
(Gelfoam and SurgiCel) with and Without Thrombin
Complications
SURGIFLO-treated patients were associated with a higher
risk of experiencing minor complications (OR = 1.36; 95%
CI = 1.12-1.66) compared with FLOSEAL-treated patients. No
signiﬁcant risk differences were found for major complications
(OR = 1.24; 95% CI = 0.93-1.65; p = 0.14), surgical revisions
for bleeding (OR = 1.23; 95% CI = 0.83-1.82; p = 0.31), and
mortality (OR = 0.74; 95% CI = 0.48-1.16; p = 0.19).Sealant or Hemostat Polysaccharide Powder (Reference Group)
SURGIFLO
(N ¼ 646)
Odds Ratio (95% CI)*/
Adjusted Difference†
Relative Risk‡
(95% CI) p value§
5 (10.1) 1.77 (1.28-2.46) 1.70 (1.26-2.27) o0.001
1 (23.4) 1.46 (1.16-1.83) 1.31 (1.12-1.52) 0.001
0 (3.1) 1.26 (0.76-2.09) 1.25 (0.77-2.01) 0.36
6 (4.0) 1.09 (0.68-1.74) 1.09 (0.70-1.68) 0.71
9 (81.9) 8.37 (6.60-10.62) 2.20 (2.11-2.28) o0.001
6 (12.47-15.64) 4.15 units N/A o0.001
2 (76.2) 10.36 (8.32-12.90) 3.37 (3.17-3.55) o0.001
6 (8.54-11.16) 1.76 units N/A o0.001
4 (36.2) 1.97 (1.62-2.40) 1.66 (1.45-1.88) o0.001
6 (3.29-4.53) –0.12 units N/A 0.66
3 (73.2) 5.63 (4.55-6.97) 2.33 (2.18-2.46) o0.001
1 (8.55-10.80) 1.86 units N/A o0.001
4 (12.11-13.40) 0.17 days N/A 0.53
9 (397-422) 22 minutes N/A o0.001
of stay; N/A, not applicable; PRBC, packed red blood cell.
inomial regression analyses.
ent in each group.
Table 4. Results of Group C. FLOSEAL Only () Gelfoam or SurgiCel With and Without Thrombin (Reference Group
Comparative outcomes
FLOSEAL
(N ¼ 10,180)
SURGIFLO
(N ¼ 736)
Odds Ratio (95% CI)*/
Adjusted Difference†
Relative Risk‡
(95% CI) p value§
Major complications: n (%)¶ 823 (8.1) 74 (10.1) 1.24 (0.93-1.65) 1.22 (0.94-1.57) 0.14
Minor complications: n (%)¶ 1,826 (17.9) 181 (24.6) 1.36 (1.12-1.66) 1.25 (1.09-1.43) 0.003
Surgical revision: n (%)¶ 302 (3.0) 31 (4.2) 1.23 (0.83-1.82) 1.21 (0.83-1.76) 0.31
Patient mortality: n (%)¶ 349 (3.4) 25 (3.4) 0.74 (0.48-1.16) 0.76 (0.49-1.15) 0.19
Any blood product transfusion: n (%)¶ 3,400 (33.4) 574 (78.0) 7.68 (6.29-9.38) 2.41 (2.30-2.50) o0.001
AM units (95% CI)† 10.05 (9.18-10.99) 12.92 (11.62-14.37) 2.88 units N/A o0.001
Day 1, blood product transfusion: n (%)¶ 2,346 (23.0) 525 (71.3) 8.68 (7.21-10.44) 3.45 (3.24-3.65) o0.001
AM units (95% CI)† 8.45 (7.60-9.40) 9.91 (8.78-11.18) 1.45 units N/A o0.001
Day 2-4, blood product transfusion: n (%)¶ 1,594 (15.7) 259 (35.2) 2.36 (1.97-2.82) 1.94 (1.71-2.18) o0.001
AM units (95% CI)† 4.42 (3.89-5.02) 3.57 (3.05-4.18) -0.84 units N/A 0.002
PRBC transfusion: n (%)¶ 2,873 (28.2) 516 (70.1) 6.35 (5.26-7.66) 2.59 (2.44-2.73) o0.001
AM units (95% CI)† 8.65 (7.90-9.47) 9.04 (8.13-10.05) 0.39 units N/A 0.31
Hospital LOS: AM (95% CI)† 12.83 (12.42-13.24) 12.61 (12.05-13.21) -0.21 days N/A 0.40
Surgery time: AM (95% CI)† 380 (372-387) 398 (387-409) 18 min. N/A o0.001
Abbreviations: CI, conﬁdence interval; AM, adjusted mean; N/A, not applicable; PRBC, packed red blood cell; LOS, length of stay.
*Odds ratios from logistic regression for all binary outcome variables.
†Ratios and adjusted mean value for each group from GLM negative binomial regression analyses.
‡Relative risk converted from adjusted odds ratio and percentage of event in each group
§all p values from logistic regressions or GLM.
¶n (%) from unadjusted frequency tables.
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SURGIFLO-treated patients were associated with an
increased risk for transfusions: Any blood product (OR =
7.68; 95% CI = 6.29-9.38; po 0.001), day 1 (OR = 8.68;
95% CI = 7.21-10.44; po 0.001), and day 2 to day 4 blood
product (OR = 2.36; 95% CI = 1.97-2.82; po 0.001), and
PRBC (OR = 6.35; 95% CI = 5.26-7.66; po 0.001).
SURGIFLO-treated patients received more transfused units of
any blood product (AD = 2.88 units; po 0.001) and day 1 blood
product (AD = 1.45 units; po 0.001) compared with FLOSEAL.
SURGIFLO-treated patients received fewer day 2 to day 4 blood
product units (AD = –0.84 units; p = 0.002) than FLOSEAL
patients. No signiﬁcant difference was found between groups in
transfused PRBC units (AD = 0.39 units; p = 0.31).
Healthcare Utilization
No difference in hospital LOS between the 2 groups was
found (AD = –0.21 days; p = 0.40). SURGIFLO-treated
patients had longer surgery times (AD = 18 minutes;
p o 0.001), compared with FLOSEAL patients.
DISCUSSION
Active ﬂowable hemostatic matrices contain gelatin and
thrombin in a single-application product. The dual mechanism
of action for these products includes contact activation and
active biologic agents (ie, thrombin) to assist the body’s own
clotting cascade to stop bleeding. These products work by
blocking blood ﬂow and actively converting blood ﬁbrinogen
into ﬁbrin at the site of bleeding.13 Two commonly used active
ﬂowable hemostatic agents in the US are FloSeal Hemostatic
Matrix and Surgiﬂo Hemostatic Matrix. These ﬂowable hemo-
stats have many advantages, including rapid hemostasis and
precise application, as the gelatin in the ﬂowable product ﬁlls
the wound and conforms to its shape, allowing surgeons
versatility with delivery and effective tissue contact.Multiple prospective, randomized, controlled trials across
numerous surgical areas have reported an active ﬂowable
hemostatic matrix (FLOSEAL) to be a more effective hemostat,
demonstrating faster hemostasis and better outcomes compared
with passive nonﬂowable hemostatic agents (eg, GELFOAM or
SURGICEL).6,11–13 Research also indicates the use of an active
ﬂowable hemostatic matrix (FLOSEAL) is associated with fewer
post-surgical complications,6,19,20 surgical revisions,6,21 and
blood transfusions,6,7,21 as well as shorter surgical times,10,21,22
compared with other common passive topical hemostats.
Research comparing the clinical performance and out-
comes between the most commonly used active ﬂowable
topical hemostatic matrices (FLOSEAL and SURGIFLO) in
cardiac surgery has been limited. Two porcine animal studies
compared these hemostatic matrices, with both studies report-
ing that FLOSEAL stopped bleeding more effectively than
SURGIFLO þ thrombin, demonstrating faster and more
effective hemostasis. Evidence from these animal studies
found differences in the active ﬂowable hemostats gelatin
granules.5,14 As reported from these animal studies, the
difference in the performance of these active ﬂowable hemo-
stats is thought to be due to the composition of the gelatin
granules. Gelatin granule characteristics such as, but not
limited to, species type (bovine v porcine), various shapes
and sizes, smoothness, surface areas, and optimal thrombin/
ﬁbrinogen ratios may lead to performance differences.5,14
However, transferability of these performance differences in
animal models to real-world patient outcomes has not been
studied.
Currently, this study represents the ﬁrst and largest known
clinical outcomes evaluation of the effectiveness of these two
hemostatic matrices in a large surgical patient population,
based on associated outcomes and usage patterns. Using the
Premier US Perspective Hospital Database allowed for an
analysis of outcomes, including complications and transfusions,
based on cardiac surgeon usage.
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patients were associated with better patient outcomes (ie,
reduction in complications and healthcare resource utilization)
compared with SURGIFLO-treated patients, across all the
study groups. Group A results indicated FLOSEAL-treated
surgical cases were associated with better outcomes compared
with SURGIFLO, without the inﬂuence of other active and
passive hemostats on this surgical population. Differences in
major complications and surgical revisions for bleeding were
signiﬁcant in group A; however, when other additional active
and passive hemostats were applied to patients (groups B and
C), these outcomes became less signiﬁcant. Different factors
could have accounted for these differences, such as the timing
of surgical application or anatomic placement of these other
hemostats and sealants. Because these data were not available,
the extent to which they played a role is uncertain. Despite this,
differences in minor complications, transfusion (rates and
units), and surgery time between the two products were the
most signiﬁcant and consistent across all study groups.
To better understand the inﬂuence confounding factors may
have had on the results, separate regression modeling analyses
were performed with expanded study covariates. For instance, All
Patient Reﬁned (APR) severity initially was included as a
covariate in the logistic regression models for major/minor
complications. The goodness of ﬁt of the model with this variable
included was 0.92þ (c statistic); however, this variable was
thought to overlap with the major or minor complications
outcome variable and was excluded due to lack of independence.
For consistency, APR severity also was excluded from the GLM
regression models. Additionally, the locale of the hospital (urban v
rural) variable was included initially as a covariate in the
regression model; however, the results were the same as when
the variable was excluded, so the ﬁnal model did not include
urban/rural status of the hospital. Selected patient and hospital
characteristics were reduced to the ﬁnal 9 confounding factors
outlined in the Methods section as a result of these subanalyses.
Because there were both hospital-level and patient-level
covariates in this study, sensitivity analyses were performed to
determine the best statistical approach for handling two levels
of analysis. In addition to analyzing the data in a non-
hierarchical fashion, as outlined in the Methods section,
regression analyses without hospital-level covariates also were
conducted to assess the estimate changes. Because no signiﬁ-
cant changes in the two sets of estimates were noted and the
general assumption that the outcome was affected more by the
observable patient demographics, comorbidities, treatment, and
hospital characteristics than the unobserved hospitalcharacteristics, especially when observing large numbers of
observations, the non-hierarchical approach was selected as the
ﬁnal method for ease of interpretation.
FLOSEAL groups in the study were far larger than SURGI-
FLO groups, which was anticipated given the following: (1)
FLOSEAL was approved by the US FDA in 1999 and was
available for use in 2000, representing a substantially longer
time on the market compared with SURGIFLO, which was
available in 2006 and (2) FLOSEAL has a larger market share
(volume-based) in the US across all major surgical specialties.
Given real-world study objectives, the authors did not want to
preselect or truncate the data from the surgical population,
because this would negate the objective of the study.
The present study had the inherent limitations of conducting
retrospective database analyses, which should be considered
because they may impact or limit generalizability of ﬁndings.
The database did not allow for the assessment of potential
physician differences (such as skill and experience), the assess-
ment of long-term outcomes (because post-discharge data were
not available), or the inclusion of diagnoses and/or procedures that
were not coded. Additionally, transfusion practices in the US are
not standardized across hospitals, and as such, transfusion results
may reﬂect practice variations. However, study strengths included
(1) a large assessment of cases from a large number of hospitals
and physicians geographically dispersed across the US, (2)
representation of real-world teaching and non-teaching hospital
data, and (3) date-stamped detailed data on hemostatic agent use,
complications, and healthcare resource utilization, not commonly
found in databases.CONCLUSION
The present study yielded important information for the
healthcare community. Using the Premier US Perspective Hospital
Database allowed for a retrospective analysis of patient outcomes
with a large sample size. Results in this cardiac surgery population
found that SURGIFLO-treated patients were associated with
signiﬁcantly higher risks of complications, transfusions (rates
and units), and longer surgery time than the FLOSEAL-treated
patients. Although these products are both active gelatin-based
hemostatic matrices, performance differences found in prior
animal studies and this large human study have implications for
healthcare providers. Avoidance of complications, transfusions,
and healthcare resource utilization for cardiac surgery may present
clinical and economic beneﬁts for patients, physicians, hospitals,
and payers. Future research should evaluate active ﬂowable gelatin
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